1 The potential effect of romosozumab on perioperative management for

2 instrumentation surgery

- 3
- 4 Koji Ishikawa^{1,2,3*}, Soji Tani¹, Tomoaki Toyone¹, Koki Tsuchiya¹, Tomoko Towatari¹, Yusuke Oshita⁴, Ryo
- 5 Yamamura¹, Takashi Nagai^{1,5}, Toshiyuki Shirahata⁶, Katsunori Inagaki¹, Yoshifumi Kudo¹
- 6

7	¹ Department o	f Orthopaedic	Surgery, School	of Medicine, Showa	University, Tokyo, Japan
	1	1		,	

- 8 ² Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan
- 9 ³ Department of Orthopaedic Surgery, Duke University, North Carolina, USA
- ⁴ Department of Orthopaedic Surgery, Showa University Northern Yokohama Hospital, Kanagawa, Japan
- ⁵ Department of Rehabilitation Medicine, School of Medicine, Showa University, Tokyo, Japan
- 12⁶ Department of Orthopaedic Surgery, Showa University Koto Toyosu Hospital
- 13
- 14 *Corresponding author: Koji Ishikawa (K.I)
- 15 Department of Orthopaedic Surgery, School of Medicine, Showa University, Tokyo, Japan
- 16 Address: Building No.6, room517, 1-5-8 Hatanodai, Shinagawa, Tokyo 142-8666, Japan
- 17 Tel: +81 3 3784 8543 Fax: +81 3 3784 9005
- 18 Email: koji.ishikawa@med.showa-u.ac.jp, ORCID ID: 0000-0003-3689-5662

- 20 Competing Interest Statement
- 21 K.I. and T.N. received a speaking fee from Amgen.

22 Abstract

23 Background: Age-related changes in bone health increase the risk for complications in elderly patients undergoing orthopedic surgery. Osteoporosis is a key therapeutic target that needs to be addressed to 24 25 ensure successful instrumentation surgery. The effectiveness of pharmacological interventions in 26 orthopedic surgery, particularly the new drug romosozumab, is still unknown. We aim to evaluate the 27 effect of 3-month romosozumab treatment on biomechanical parameters related to spinal instrumentation 28 surgery, using the Quantitative Computed Tomography (QCT)-based Finite Element Method (FEM). 29 Methods: This open-labeled, prospective study included 81 patients aged 60 to 90 years, who met the 30 osteoporosis criteria and were scheduled for either romosozumab or eldecalcitol treatment. Patients were 31 assessed using blood samples, dual-energy absorptiometry (DXA), and QCT. Biomechanical parameters 32 were evaluated using FEM at baseline and 3 months post-treatment. The primary endpoints were 33 biomechanical parameters at 3 months, while secondary endpoints included changes in regional volumetric bone mineral density around the pedicle (P-vBMD) and vertebral body (V-vBMD). 34 Results: Romosozumab treatment led to significant gains in P-vBMD, and V-vBMD compared to 35 36 eldecalcitol at 3 months. Notably, the romosozumab group showed greater improvements in all biomechanical parameters estimated by FEM at 3 months compared to the eldecalcitol group. 37 Conclusion: Romosozumab significantly increased the regional vBMD as well as biomechanical 38 parameters, potentially offering clinical benefits in reducing post-operative complications in patients with 39 40 osteoporosis undergoing orthopedic instrumentation surgery. This study highlights the novel advantages of romosozumab treatment and advocates further research on its effectiveness in perioperative 41 42 management.

43 Introduction

44 Recent medical advancements have significantly increased life expectancy, leading to a rise in the number

45 of aged patients undergoing surgeries (1–3). The significant shift in the aging population highlights

46 osteoporosis as an enormous problem in orthopedic surgery due to its impact on postoperative

47 complications (4–6).

48 Osteoporosis, a global health concern, is not only an essential therapeutic target for extending healthspan,

49 but also lifespan (7–9). Recent research has further investigated the links of osteoporosis with orthopedic

50 surgery, aiming to optimize operative outcomes (10–13). Specifically, if instrumentation spinal surgery is

51 indicated, adequate risk stratification, including bone health, is advocated to ensure optimal and safe

52 outcomes, since bone fragility exacerbates postoperative complications such as loosening, junctional

53 failure, and cage subsidence, potentially resulting in revision surgery. Indeed, previous studies have

reported that 25-60% of patients with osteoporosis experienced postoperative complications, even

55 following successful instrumentation surgery (14–16).

While dual-energy absorptiometry (DXA) is a reliable method for assessing bone health, earlier imaging 56 57 studies highlight the heterogeneity of the bone mineral density (BMD) inside the vertebra, which is overlooked by DXA measurement (17). Additionally, recent findings indicate that regional volumetric 58 59 bone mineral density (vBMD) around an implant, as measured by QCT, demonstrates stronger 60 correlations with both intraoperative screw fixation and postoperative complications, including screw 61 loosening and cage subsidence, compared to areal bone mineral density (aBMD) assessed by DXA. 62 (6,18,19). Furthermore, Keaveney et al. demonstrated the superiority of CT-based biomechanical 63 analysis over BMD testing alone in terms of predicting reoperation following spinal instrumentation 64 surgery (5). Thus, a multidisciplinary approach including bone health assessment of the heterogeneity of 65 the BMD in the vertebra as well as biomechanical analysis is recommended prior to surgery to an ensure

66 optimal and safe outcome.

67 Pharmacologic therapy could play an important role in perioperative bone management for facilitating 68 bone health, but its effectiveness for orthopedic implant surgery has not been systematically investigated 69 (12,20). The possible advantage of osteoporosis treatments for instrumentation surgery, including 70 teriparatide and bisphosphonate, specifically addressing issues like screw loosening and adjacent vertebral 71 fractures, have been reported previously (18,20–23). Although the contribution of BMD to cage 72 subsidence is described, to the best of our knowledge, there is no study examining the effects of 73 osteoporosis treatment for cage subsidence (19). A significant challenge in biomechanical implant 74 analysis in the clinical, particularly during pharmacological intervention, is the inability to conduct 75 damage or destruction analysis. Our recent in silico biomechanical analysis using Finite Element Method 76 (FEM) challenges these limitations, and showed that a 12-month course of denosumab treatment (an anti-77 RANKL antibody) is potentially beneficial for reducing postoperative screw loosening following spinal 78 instrumentation surgery (18). This study lays the groundwork for understanding the impact of 79 osteoporosis treatment on optimizing outcomes in instrumentation surgery. However, considering the 80 onset of postoperative complications within the initial few months after surgery, there is a pressing need 81 for treatments that show benefits quickly following administration (16). 82 Although increasing evidence suggests that osteoporosis treatment positively impacts orthopedic surgery, 83 no standard approach exists for perioperative management. A substantial hurdle when incorporating osteoporosis treatments into surgical strategies is the extended time frame, typically around a year, 84 85 required for the improvement of bone structure after treatment initiation. However, for patients requiring 86 immediate surgery, delaying procedures for the benefits of osteoporosis treatment is not a viable option. This presents a challenge in determining the optimal timing and effectiveness of osteoporosis treatment 87

88 for patients in need of immediate surgical intervention. Romosozumab may offer a solution to this issue,

89 given that previous reports have shown its potential to increase BMD shortly after treatment

90 administration in terms of both imaging and bone biopsy assessment (24–26).

91 Thus, we aim to evaluate the effects of a 3-month romosozumab treatment on spinal instrumentation
92 surgery using QCT-based FEM. We have extended our earlier FEM methods to cover analysis for the

risk of cage subsidence, a major complication that occur in 5-50% of cases following surgery and is
linked with negative clinical outcomes (19). Here, we first demonstrated the potential benefits of shortterm romosozumab treatment in improving bone health and reducing postoperative complications in
patients with osteoporosis undergoing spinal instrumentation surgery.

97

98 Methods

99 Study subjects

100 This was an open-labeled prospective study of ambulatory patients 60 to 90 years of age who met the osteoporosis criteria (27). Between March 2019 and March 2021, 226 patients who were scheduled for 101 102 Romosozumab (Romo) or Eldecalcitol (ELD) treatment, were assessed for inclusion, of which 81 patients 103 participated in the present study. The exclusion criteria were patients with illnesses affecting bone and calcium metabolism or bone disorders other than osteoporosis, any malignant conditions, fresh fracture, 104 scheduled surgery, severe renal dysfunction or history of cardiovascular events. The patients were 105 106 divided into two groups based on their treatment (Romo: 69 patients, ELD: 12 patients). All patients 107 received daily eldecalcitol (0.75 μ g) and / or calcium (400-800 mg) except for four patients in the Romo 108 group. These four exceptions were decided by physicians based on their baseline serum calcium levels to 109 prevent hypercalcemia. The medication compliance related to eldecalcitol and calcium was assessed at 110 each visit and it was confirmed that all patients consumed > 90% of the drugs over the course of the study. The study was approved by the local ethics committees of Yamanashi Red Cross Hospital and in 111 accordance with the precepts of the Declaration of Helsinki. All patients provided informed consent 112 113 before participation.

114 Assessments

115 We measured the spine-areal BMD (spine-aBMD) using DXA (L1-4) (Hologic QDR series: Hologic,

116 Waltham, MA) at baseline and 6 months. All DXA measurements were analyzed by a radiologist at a

117 central site. The regional vBMD around the pedicle (P-vBMD) and vertebral body (V-vBMD) as well as

biomechanical parameters were measured by QCT-based FEM at baseline and 3 months. The intra- and
inter-observer coefficients of variation of BMD assessments have been previously described (6,18,28)
The serum levels of albumin, calcium, and phosphorus as well as estimated glomerular filtration rate
(eGFR) were evaluated at baseline. The bone turnover markers including serum levels of TRACP-5b and
total-P1NP were assessed at baseline, then at 3 and 6 months following treatment. The primary endpoints
were the biomechanical parameters at 3 months. Secondary endpoints included the changes in regional
vBMD and bone turnover markers throughout the study.

125 Three-dimensional volumetric bone mineral density

126 The details of the measurement of vBMD have been described in previous studies (6,18,29,30). CT data

127 were acquired with a SOMATOM Definition AS+ multidetector-row CT scanner (Aquilion 16; Toshiba

128 Medical Systems, Otawara, Japan) using predefined scanning conditions (x-ray energy, 120 kV; x-ray

129 current, SD20; rotation speed, 0.5 s/rot; beam pitch, 0.95). For QCT scanning, a phantom (Mindways,

130 Austin, TX, USA) was placed underneath the patients for BMD calibration, thereby ensuring

131 measurement quality throughout the study. The vBMD at the vertebral body and pedicle (reference

132 vertebra L4) was measured using MECHANICAL FINDER (Research Center of Computational

133 Mechanics; version 10.0, Tokyo, Japan) (Fig.1, Fig. S1). We selected the L3 vertebra if the L4 vertebra

had a grade 2 or 3 fracture by using a semiquantitative method (31).

135 Finite Element Methods

136 Biomechanical parameters related to spinal instrumentation including compression strength (CS), pullout

strength of the screw (POS) and cage subsidence strength (CSS) were evaluated by QCT-based FEM

138 using MECHANICAL FINDER. The FEM modeling methods were based on previous studies and are

shown in Fig.1 and Movie.S1-4 (18,32). Briefly, finite element models of the L4 vertebrae were

140 constructed from the CT data and examined for the CS (Movie.S2). Then, a pedicle screw and cage were

141 placed according to the spinal fusion surgery so as to evaluate the POS and CSS (18) (Movie.S3, 4). In

142 the CSS model, a banana-shaped PEEK (polyetheretherketone) cage, which was created using

143 Metasequoia 4 (tetraface Inc., Tokyo, Japan), was set 4-mm behind the anterior edge of the upper endplate vertebrae according to the spinal fusion surgery so as to assess the risk of cage subsidence. A 144 145 compressive displacement was applied to the cage at the cranial end of the vertebrae at ramped displacement increments of 0.02 mm / step. The predicted CCS was identified by a rapid decrease in the 146 force-displacement curve or a rapid increase in the failure elements. The detailed finite element models 147 and materials properties are provided in Table S1.

149 Statistical analysis

150 Fisher's exact test and the Mann-Whitney U test were used to compare differences between the 2 groups.

151 Dunn's test was used for multiple comparisons. The correlations between each parameter were

determined using Spearman's rank coefficients. Statistical analyses were performed using Stat Flex Ver. 6 152

153 (Artech, Tokyo). All statistical tests were two tailed and results with P-values < 0.05 were considered 154 statistically significant.

155

148

Results 156

Patients and baseline demographics 157

158 Sixty-six patients in the Romo-group (66 / 69 patients, 95.7%) and 10 patients in the ELD-group (10 / 12 patients, 83.3%) completed the 6 months study follow-up (Romo: 66 / 69 [95.7%], ELD: 10/12 [83.3%], 159 160 P = ns)(Fig.S1). The reasons for the discontinued study were as follows; loss of motivation (1 patient in 161 Romo, 2 patients in ELD), hospital administration related to vascular event (1 patient in Romo), death 162 unrelated to treatment (1 patient in Romo). Table 1 shows the demographics and baseline characteristics 163 of the groups. Serum TRACP-5b and P1NP were higher in the ELD group, presumably due to a 164 difference in the prior treatment history, but the difference was not significant. BMD measured by DXA 165 and QCT was equivalent in the two groups.

Safety 166

167 The patients observed to undergo adverse events were 21 (30.4%) in the Romo and no patients in the 168 ELD (Fig. S3). Injection-site reactions such as redness, tenderness and swelling were reported by 16 169 patients (23.2%) in Romo group. These reactions were well recognized at the initial injection (50.0%). 170 Among the patients who had injection-site reactions, five patients (7.3%) experienced these reactions multiple times during the study (Fig. S4). One (1.5%) patient had hypocalcemia and one (1.5%) patient 171 had hypercalcemia in the Romo group, both of which were of mild severity and asymptomatic. 172 Gastroenteritis was observed in one (1.5%) patient. Two (2.9%) patients in the Romo group had severe 173 174 adverse events including one stroke and one death leading to treatment discontinuation, neither of which 175 was thought to be related to the treatment. 176 Changes in bone turnover markers showed dual effects of Romosozumab The changes in the total P1NP and TRACP-5b levels are shown in Fig. S5. In the Romo group, the P1NP 177 178 level reached its highest value at 3 months (P < 0.001, vs. Baseline), followed by a gradual decrease at 6 179 months. Percentage changes from baseline of total P1NP was higher in the Romo group compared to the ELD group at 3 and 6 months (all P < 0.001). The P1NP level decreased significantly over the course of 180 181 the study in the ELD group (3 months; P < 0.01, 6 months; P < 0.01, vs. baseline). The TRACP-5b levels 182 decreased significantly in both groups at 3 and 6 months, and there was no significant difference between 183 groups.

184 Greater increases in regional BMD in Romo group

185 The median percentage changes from baseline in aBMD by DXA at 6 months was 6.61% (Q1/Q3: 2.62 /

186 12.7) in the Romo group and 0.91% (0.25 / 2.06) in the ELD group (P < 0.001) (Fig. S6a). The 3D-

187 modeling of the vertebrae demonstrates the heterogeneity of the vertebral BMD that is undetectable by

188 DXA measurement. (Fig. 2a). The difference between the groups observed at 6 months was already

- identifiable in the regional BMD measurement at 3 months (Fig. 2b-e). The Romo group exhibited
- 190 significantly greater increases in regional BMD including the vertebral body and pedicle at 3 months
- 191 compared to the ELD group (V-vBMD; Romo vs. ELD: 10.43% [4.39 / 16.77] vs. 1.54% [-4.45 / 2.48], P

192 < 0.001 and P-vBMD; 12.75% [4.94 / 18.08] vs. 2.22% [-0.35 / 5.13], P < 0.001) (Fig. 2f). Remarkably,

193 treatment with romosozumab resulted in noticeable BMD increases not only within the inner pedicle

region (corresponding to ROI of the P-vBMD) but also on the cortical surface of the inner pedicle (Fig.

195 2b, d, e). Similarly, the BMD around the endplate, the corresponding area for cage placement in spinal

- 196 fusion surgery, increased following romosozumab treatment (Fig. 2d, e). In treatment-naïve patients,
- 197 while the results were consistent, the group differences were more evident (aBMD: 9.05% [5.13 / 14.4]

198 vs. 0.95% [0.57 / 2.56], P < 0.001, V-vBMD: 12.84% [5.75 / 20.88] vs. 1.33% [-5.37 / 2.11], P < 0.0001

and P-vBMD: 12.75% [4.94 / 17.49] vs. 1.22% [-0.44 / 5.30], P < 0.001,) (Figs. 2g, S6b).

200 Significant improvement in biomechanical parameters in the Romo group

201 Greater gains in the percentage changes from baseline were observed in the Romo group than in the ELD

group in all of the biomechanical parameters (compression strength: 11.49% [2.04 / 22.55] vs. 0.74% [-

203 2.85 / 6.89], pullout strength: 20.00% [9.09 / 33.33] vs. 0.00% [0.0 / 10.00], cage subsidence strength:

204 11.19% [3.08 / 25.31] vs. -0.55% [-6.36 / 4.30], P < 0.01, P < 0.001, P < 0.001, respectively) (Fig. 3d).

205 This results were bolstered by the distribution of yield risk and crushed element, which further illustrates

206 the significant improvement following romosozumab treatment (Fig. 3a-c). The findings are consistent

207 among treatment-naïve patients (compression strength: 13.60% [1.81 / 24.1] vs. 2.50% [-3.74 / 7.21],

208 pullout strength: 20.00% [0.00 / 33.33] vs. 0.0% [0.0 / 8.89], cage subsidence strength: 18.27% [3.26 /

209 28.11] vs. -1.97% [-6.61 / 4.38], P < 0.01, P < 0.01, P < 0.001, respectively) (Fig. 3d). Collectively, these

210 findings suggest a potential contribution of 3 months of romosozumab treatment to the reduction of

211 postoperative complications in instrumentation surgery.

212 Regional vBMD had the most significant correlations with biomechanical parameters

213 Local areal contribution around the implant, as displayed in each biomechanical analysis in Figure 3, led

us to examine the correlation between biomechanical parameters with various BMD assessments. The

correlations between the BMD and biomechanical parameters are summarized in Table 2. While the

aBMD demonstrated mild or no correlations with the biomechanical parameters, the strongest correlations
were observed with the regional vBMD across all parameters in both groups.

218

219 **Discussion**

Despite the longstanding recognition through intensive research of osteoporosis as a risk factor for
 postoperative complications in orthopedic instrumentation surgery, these complications persist as a
 primary concern and critical priority for surgeons. This challenge is becoming more prominent with the
 worldwide increase in the aged population (33,34).

224 One significant limitation of biomechanical implant assessment for surgery, particularly in clinical

practice, is the inability to conduct damage or destruction analysis, a method traditionally applied in

animal and human cadaver research (35,36). This issue, therefore, presents a difficulty for surgeons when

they are trying to determine the effectiveness of osteoporosis treatments in mitigating postoperative

228 complications. Our in silico biomechanical analysis, utilizing patient QCT data collected during

treatment, offers a broader perspective, and contributes novel insights to the field of bone and implantresearch.

In this study, romosozumab treatment was associated with larger gains in spine BMD at 6 months, as

232 measured by DXA, consistent with previous trials (24,37,38). The difference observed at 6 months was

already evident at 3 months, confirmed by regional vBMD in both the vertebral body and pedicle.

Remarkably, this change began soon after treatment administration, associated with improvements in

235 FEM-estimated biomechanical parameters such as vertebral compression strength, screw pullout strength,

and cage subsidence strength. It is noteworthy that these parameters are closely linked with common

237 postoperative complications, suggesting the potential benefits of romosozumab for perioperative

238 management. The notable gains in the both the BMD and FEM-estimated parameters are likely attributed

to the dual mechanisms of romosozumab, namely, the enhancement of bone formation and reduction of

bone resorption, as demonstrated by the evaluation of bone turnover markers (39–41).

241 Several strategies have been proposed for managing osteoporosis in patients undergoing spinal surgery, with a broad consensus emphasizing the need for preoperative bone health assessment (11–13). If poor 242 243 bone health condition is detected, initiation of pharmacological treatment is recommended. Moreover, considering the risk of postoperative complications in patients with osteoporosis, Lubelski and colleagues 244 245 suggest postponing surgery in order to strengthen the bone prior to the procedure (12). In the light of 246 increases in regional vBMD and potential risk reduction post-surgery shortly after the treatment 247 administration in this study, romosozumab may emerge as a valuable preoperative therapeutic option. This is particularly significant, given that the effectiveness of most osteoporosis therapies is typically not 248 249 recognized until one or two years after treatment.

250 Limitations in DXA's capacity to predict future fractures and postsurgical complications, arising from 251 factors like BMD heterogeneity in the vertebra, osteophyte formation, articular facet hypertrophy, and 252 aortic calcification, are further supported in the present study (5,6.42). We found that all of the 253 biomechanical parameters exhibit their strongest correlations with vBMD around the implant. This 254 implies a significant contribution of region-specific vBMD in postoperative complications. As potential 255 DXA limitations like overestimation of BMD is prevalent in patients with a spinal disorder, evaluation of 256 regional vBMD might yield more clinical utility in assessing the risk of surgery. Furthermore, with the 257 distinct post-treatment changes in regional BMD, along with superior correlations of corresponding 258 regional vBMD with biomechanical parameters, understanding the therapeutic effects of specific regional 259 vBMD could offer potentially valuable insights over traditional DXA assessment for surgeons. However, 260 this hypothesis needs further investigation.

Previous studies on the effects of romosozumab showed increases in both cortical BMD and cortical thickness (25,43). Genant et al. reported that most significant changes in the cortical area predominantly occur in the endocortical region (44). Furthermore, histomorphometry analysis of bone biopsies from a clinical trial showed that the anabolic effect in the initial 2 months of romosozumab treatment mainly arises on the endocortical surface, leading to a 18.3% increase in the mineralizing surface compared to a 4.1% increase in the trabecular bone (26,45). Even though we did not scrutinize parameters related to the

cortical and endocortical area due to their ambiguous definition and the limited resolution of imaging
studies, we did find that the vBMD in the pedicle responded more favorably to treatment than in the
vertebral area. These insights could potentially support previously mentioned studies, given that PvBMD region of interest presumably includes the endocortical area, whereas V-vBMD mainly comprises
trabecular bone.

272 Consistent with a previous report, romosozumab was generally well tolerated, with no new safety 273 findings observed (24). The most frequently observed adverse events were injection site reactions, which 274 some patients experienced multiple times. While two severe events were noted, the frequency of these 275 events was similar to previous studies (24,38). Although safety concerns, including cardiovascular risk, 276 were raised by romosozumab when compared with alendronate, this risk was not observed in a placebo-277 controlled trial (24,41,46). In addition, recent studies have shown that romosozumab is not associated 278 with an increased rate of adverse events, regardless of levels of kidney function (47). Nevertheless, 279 careful assessment, including the risk of a cardiovascular event, is desired prior to romosozumab 280 initiation. Moreover, the safety profiles of osteoporosis treatment need to be assessed in the perioperative 281 setting.

282 This study has several limitations. The first is the non-randomized, open-label design, which was 283 necessitated by the differential effectiveness of each drug in preventing fractures, particularly among our 284 study population, which consisted of patients with relatively severe osteoporosis. Consequently, patient choice followed expert consultation, leading to a disparity in the number of patients in each group. While 285 286 there was an open-label nature of the treatment assignments, the primary outcomes were measured by 287 investigators who were masked to the group allocation. Another limitation was the small samples size, 288 affecting our power to detect differences between groups. However, the romosozumab groups exhibited 289 significant improvement in primary outcomes, and the sample size was relatively large compared to 290 previous implant-related FEM studies (18,32). In addition, although FEM have been validated in earlier 291 study, our FEM model could not fully mimic the clinical situation (32). Nevertheless, conducting damage 292 or destruction analysis in the clinical setting is inherently impractical. Finally, we were unable to evaluate

293 bone fusion and reoperation rates, one of the endpoints of spinal instrumentation surgery. Nonetheless, 294 both the rigid screw fixation and reduced cage subsidence were potentially facilitated by romosozumab, 295 and thus could beneficially contribute to bone fusion. Further study is warranted to support this notion. 296 The strengths of this study include the use of a variety of complementary imaging modalities to evaluate 297 the effect of romosozumab on instrumentations surgery, yielding consistent and complementary results. 298 Throughout our novel biomechanical approach, we first established the impact of instrumentation surgery 299 based on the region-specific BMD alternations observed following romosozumab treatment. Such 300 assessments are often a challenge for traditional biomechanical methods, particularly when drugs are 301 involved in the clinical setting. While the present findings highlight a unique benefit of romosozumab for patients with osteoporosis undergoing instrumentation surgery, it is imperative to standardize a 302 303 multidisciplinary approach, including osteoporosis assessment and treatment, prior to implantation 304 surgery in order to maximize the chance of securing long-term success.

305

306 Acknowledgements

307 We would like to express our sincere gratitude to the staff at the Department of Orthopaedic Surgery at

308 Showa University for their helpful discussion and assistance. We are also grateful to Hideyuki Mimata

309 for the valuable technical assistance. Finally, we thank Ayano Oyamada, Kei Gonsho and Miho

310 Mochizuki for their cooperation in collecting clinical data.

311 **References**

- Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, et al. Estimate of the global volume of surgery in 2012: an assessment supporting improved health outcomes. Lancet.
 2015;385:S11.
- James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858.
- Etzioni DA, Liu JH, Maggard MA, Ko CY. The Aging Population and Its Impact on the Surgery
 Workforce. Ann Surg. 2003;238(2):170–7.
- Punnoose A, Claydon-Mueller LS, Weiss O, Zhang J, Rushton A, Khanduja V. Prehabilitation for Patients Undergoing Orthopedic Surgery: A Systematic Review and Meta-analysis. JAMA Netw Open. 2023;6(4):E238050.
- Keaveny TM, Adams AL, Fischer H, Brara HS, Burch S, Guppy KH, et al. Increased risks of vertebral fracture and reoperation in primary spinal fusion patients who test positive for osteoporosis by Biomechanical Computed Tomography analysis. Spine J [Internet].
 2023;23(3):412–24. Available from: https://doi.org/10.1016/j.spinee.2022.10.018
- 328 6. Ishikawa K, Toyone T, Shirahata T, Kudo Y, Matsuoka A, Maruyama H, et al. A Novel Method
 329 for the Prediction of the Pedicle Screw Stability. Clin Spine Surg. 2018;31(9):E473–80.
- Bliuc D, Nguyen ND, Milch VE, Nguyen T V., Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA.
 2009;301(5):513–21.
- Center JR, Bliuc D, Nguyen ND, Nguyen T V., Eisman JA. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011;96(4):1006–14.
- Abrahamsen B, Osmond C, Cooper C. Osteoporosis: Treat or let die twice more likely. J Bone Miner Res. 2015;30(9):1553–9.
- 337 10. Miller AN, Lake AF, Emory CL. Establishing a fracture liaison service: An orthopaedic approach.
 338 J Bone Jt Surg Am Vol. 2015;97(8):675–81.
- Sardar ZM, Coury JR, Cerpa M, Dewald CJ, Ames CP, Shuhart C, et al. Best Practice Guidelines for Assessment and Management of Osteoporosis in Adult Patients Undergoing Elective Spinal Reconstruction. Spine (Phila Pa 1976). 2022;47(2):128–35.
- Lubelski D, Choma TJ, Steinmetz MP, Harrop JS, Mroz TE. Perioperative medical management of spine surgery patients with osteoporosis. Neurosurgery. 2015;77(4):S92–7.
- Zhang A, Khatri S, Balmaceno-Criss M, Alsoof D, Daniels AH. Medical optimization of
 osteoporosis for adult spinal deformity surgery: a state-of-the-art evidence-based review of current
 pharmacotherapy. Spine Deform [Internet]. 2022;11(3):579–96. Available from:
 https://doi.org/10.1007/s43390-022-00621-6
- 14. Chang HK, Ku J, Ku J, Kuo YH, Chang CC, Wu CL, et al. Correlation of bone density to screw
 loosening in dynamic stabilization: an analysis of 176 patients. Sci Rep [Internet]. 2021;11(1):1–7.
 Available from: https://doi.org/10.1038/s41598-021-95232-y
- Bredow J, Boese CK, Werner CML, Siewe J, Löhrer L, Zarghooni K, et al. Predictive validity of
 preoperative CT scans and the risk of pedicle screw loosening in spinal surgery. Arch Orthop
 Trauma Surg. 2016;136(8):1063–7.

- Pearson HB, Dobbs CJ, Grantham E, Niebur GL, Chappuis JL, Boerckel JD. Intraoperative
 biomechanics of lumbar pedicle screw loosening following successful arthrodesis. J Orthop Res.
 2017;35(12):2673–81.
- 17. Kaiser J, Allaire B, Fein PM, Lu D, Adams A, Kiel DP, et al. Heterogeneity and Spatial
 Distribution of Intravertebral Trabecular Bone Mineral Density in the Lumbar Spine Is Associated
 With Prevalent Vertebral Fracture. J Bone Miner Res. 2020;35(4):641–8.
- Tani S, Ishikawa K, Kudo Y, Tsuchiya K, Matsuoka A, Maruyama H, et al. The effect of
 denosumab on pedicle screw fixation: a prospective 2-year longitudinal study using finite element
 analysis. J Orthop Surg Res. 2021;16(1):1–10.
- Parisien A, Wai EK, Elsayed MSA, Frei H. Subsidence of Spinal Fusion Cages: A Systematic
 Review. Int J Spine Surg. 2022;16(6):1103–18.
- 20. Zhang Y, Jiang Y, Zou D, Yuan B, Ke HZ, Li W. Therapeutics for enhancement of spinal fusion:
 A mini review. J Orthop Transl. 2021 Nov 1;31:73–9.
- 21. Ebata S, Takahashi J, Hasegawa T, Mukaiyama K, Isogai Y, Ohba T, et al. Role of weekly
 teriparatide administration in osseous union enhancement within six months after posterior or
 transforaminal lumbar interbody fusion for osteoporosis-associated lumbar degenerative disorders:
 A multicenter, prospective randomized study. J Bone Jt Surg Am Vol [Internet]. 2017 [cited
 2022 May 28];99(5):365–72. Available from:
- https://journals.lww.com/jbjsjournal/Fulltext/2017/03010/Role_of_Weekly_Teriparatide_Adminis
 tration_in.1.aspx
- Yagi M, Ohne H, Konomi T, Fujiyoshi K, Kaneko S, Komiyama T, et al. Teriparatide improves
 volumetric bone mineral density and fine bone structure in the UIV+1 vertebra, and reduces bone
 failure type PJK after surgery for adult spinal deformity. Osteoporos Int [Internet].
 2016;27(12):3495–502. Available from: http://dx.doi.org/10.1007/s00198-016-3676-6
- Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, et al. Comparison of teriparatide
 and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery
 in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa
 1976). 2013;38(8):487–92.
- 24. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab
 Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532–43.
- 384 25. Graeff C, Campbell GM, Peña J, Borggrefe J, Padhi D, Kaufman A, et al. Administration of
 385 romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative
 386 computed tomography and finite element analysis. Bone [Internet]. 2015;81:364–9. Available
 387 from: http://dx.doi.org/10.1016/j.bone.2015.07.036
- 26. Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, et al. Bone-Forming
 and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone
 Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of
 Treatment. J Bone Miner Res. 2019;34(9):1597–608.
- 392 27. Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, et al. Japanese 2011 guidelines for
 393 prevention and treatment of osteoporosis-executive summary. Arch Osteoporos. 2012;7(1–2):3–
 394 20.
- Ishikawa K, Nagai T, Sakamoto K, Ohara K, Eguro T, Ito H, et al. High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag. 2016;12:1831–40.
- 398 29. Tsuchiya K, Ishikawa K, Kudo Y, Tani S, Nagai T, Toyone T, et al. Analysis of the subsequent

399 400 401		treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study. Bone Reports [Internet]. 2021;14(April):101090. Available from: https://doi.org/10.1016/j.bonr.2021.101090
402 403 404 405	30.	Kuroda T, Ishikawa K, Nagai T, Fukui T, Hirano T, Inagaki K. Quadrant Analysis of Quantitative Computed Tomography Scans of the Femoral Neck Reveals Superior Region-Specific Weakness in Young and Middle-Aged Men With Type 1 Diabetes Mellitus. J Clin Densitom [Internet]. 2018;21(2):172–8. Available from: https://doi.org/10.1016/j.jocd.2017.01.005
406 407	31.	Harry K Genant, Chun Y Wu, Corner Van Kuijk, Michael C Nevitt. Using a Semiquantitative Technique. J Bone Miner Res. 1993;8(9):1137–48.
408 409 410	32.	Matsuura Y, Giambini H, Ogawa Y, Fang Z, Thoreson AR, Yaszemski MJ, et al. Specimen- specific nonlinear finite element modeling to predict vertebrae fracture loads after vertebroplasty. Spine (Phila Pa 1976). 2014;39(22):E1291–6.
411 412	33.	Arsen M Pankovich, Imad E Tarabishy. Remote nailing of intertrochanteric and subtrochanteric fractures of the femur. Instr Course Lect. 1983;32(4):303–16.
413 414	34.	Laros GS. The role of osteoporosis in intertrochanteric fractures. Orthop Clin North Am [Internet]. 1980;11(3):525–37. Available from: http://dx.doi.org/10.1016/S0030-5898(20)31455-3
415 416 417	35.	Keiler A, Schmoelz W, Erhart S, Gnanalingham K. Primary stiffness of a modified transforaminal lumbar interbody fusion cage with integrated screw fixation: Cadaveric biomechanical study. Spine (Phila Pa 1976). 2014;39(17).
418 419 420	36.	Fu X, Tan J, Sun CG, Leng HJ, Xu YS, Song CL. Intraosseous injection of simvastatin in poloxamer 407 hydrogel improves pedicle-screw fixation in ovariectomized minipigs. J Bone Jt Surg - Am Vol. 2016;98(22):1924–32.
421 422 423 424	37.	Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ, et al. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial. J Bone Miner Res. 2021;36(11):2139–52.
425 426 427 428 429	38.	Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet [Internet]. 2017;390(10102):1585–94. Available from: http://dx.doi.org/10.1016/S0140-6736(17)31613-6
430 431	39.	Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. lancet Diabetes Endocrinol. 2017 Nov;5(11):898–907.
432 433 434 435 436	40.	Xu H, Wang W, Liu X, Huang W, Zhu C, Xu Y, et al. Targeting strategies for bone diseases: signaling pathways and clinical studies. Signal Transduct Target Ther [Internet]. 2023;8(1):202. Available from: http://www.ncbi.nlm.nih.gov/pubmed/37198232%0Ahttp://www.pubmedcentral.nih.gov/articleren der.fcgi?artid=PMC10192458
437 438 439	41.	Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017;377(15):1417–27.
440 441 442	42.	Rand T, Seidl G, Kainberger F, Resch A, Hittmair K, Schneider B, et al. Impact of spinal degenerative changes on the evaluation of bone mineral density with dual energy X-ray absorptiometry (DXA). Calcif Tissue Int. 1997;60(5):430–3.

- 43. Poole KES, Treece GM, Pearson RA, Gee AH, Bolognese MA, Brown JP, et al. Romosozumab
 Enhances Vertebral Bone Structure in Women With Low Bone Density. J Bone Miner Res.
 2022;37(2):256–64.
- 446 44. Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, et al. Effects of
 447 Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in
 448 Postmenopausal Women With Low Bone Mass. J Bone Miner Res. 2017;32(1):181–7.
- 449 45. Eriksen EF, Chapurlat R, Boyce RW, Shi Y, Brown JP, Horlait S, et al. Modeling-Based Bone
 450 Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial.
 451 J Bone Miner Res. 2022;37(1):36–40.
- 46. Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C. Effectiveness and Safety of Treatments
 to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living
 Systematic Review and Network Meta-analysis for the American College of Physicians. Ann
 Intern Med. 2023;176(2):182–95.
- 456 47. Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, et al. Efficacy and
 457 Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to458 Moderate Chronic Kidney Disease. J Bone Miner Res. 2022;37(8):1437–45.

460 Table1. Baseline	patient	characteristics.
----------------------	---------	------------------

Parameters	All	Romo	ELD	
Age (years)	76.0 (70.0 / 81.3)	77.0 (70.0 / 82.3)	70.0 (75.0 / 66.5)	
Male (%)	5 (6.9)	4 (5.8)	1 (8.3)	
BMI	21.5 (19.6 / 23.4)	21.3 (19.5 / 23.1)	23.2 (21.5 / 24.6)	
Fracture history (%)	51 (63.0)	46 (56.8)	5 (41.7)	
Smoking (%)	5 (6.2)	3 (4.3)	2 (16.7)	
Alcohol (%)	4 (4.9)	3 (4.3)	1 (8.3)	
Prior treatment				
None	45 (55.6)	34 (49.3)	11 (91.7)	
Bisphosphonate	11 (13.6)	11 (15.9)	0 (0)	
SERM	3 (3.7)	3 (4.3)	0 (0)	
Denosumab	10 (12.3)	10 (14.5)	0 (0)	
Teriparatide	12 (14.8)	11 (15.9)	1 (8.3)	
Blood samples				
Albumin levels (g / dl)	4.3 (4.1 / 4.5)	4.3 (4.1 / 4.5)	4.4 (4.2 / 4.6)	
Corrected calcium levels (mg / dl)	9.4 (9.1 / 9.5)	9.4 (9.2 / 9.5)	9.2 (9.0 / 9.5)	
Phosphorus levels (mg / dl)	3.6 (3.2 / 4.1)	3.6 (3.2 / 4.1)	3.6 (3.5 / 4.0)	
eGFR (mL / min / 1.73m ²)	66.0 (55.0 / 74.0)	66.0 (54.8 / 74.0)	68.5 (61.5 / 75.0)	
Bone metabolic markers				
total-P1NP (µg / ml)	58.6 (31.3 / 86.2)	55.0 (29.2 / 81.0)	74.1 (58.6 / 115.4)	
TRACP-5b (mU / dL)	453.0 (287.3 / 571.3)	428.0 (268.8 / 560.5)	536.5 (453.0 / 689.0)	
Bone mineral density				
Spine- aBMD (g / cm ²)	0.75 (0.67 / 0.83)	0.75 (0.66 / 0.83)	0.77 (0.73 / 0.85)	
Vertebral- vBMD (mg / cm ³)	77.5 (59.5 / 91.7)	76.8 (57.5 / 91.0)	79.3 (76.2 / 95.7)	
Pedicle - vBMD (mg / cm ³)	126.1 (93.1 / 145.0)	122.4 (92.3 / 143.1)	138.0 (109.4 / 154.8)	

461 There were no statistical differences between groups for any of the parameters.

462 The data shown are the median (interquartile ranges [IQR]; Q1/Q3) or n (%). The date shown as n or n
463 (%) were analyzed by Fisher's exact test. The date presented as median IQR were analyzed by Mann-

464 Whitney U test.

465 BMI; bone mass index, SERM; selective estrogen receptor modulator, eGFR; estimated glomerular

466 filtration rate, total-P1PN; total N-terminal propeptide of type 1 procollagen, TRACP-5P; tartrate-

- 467 resistant acid phosphatase type 5 protein, aBMD; areal bone mineral density, vBMD; volumetric bone
- 468 mineral density.

	D II	Vertebral strength		Pullout strength		Cage subsidence strength	
	Baseline	r	р	r	р	r	р
	Spine- aBMD (g / cm²)	0.2640	0.0180	0.2926	0.0080	0.1103	0.3301
All	Vertebral- vBMD (mg / cm ³)	0.6387	< 0.0001	0.5096	< 0.0001	0.6108	< 0.0001
	Pedicle - vBMD (mg / cm ³)	0.5253	< 0.0001	0.6706	< 0.001	0.3463	0.0017
_	Spine- aBMD (g / cm ²)	0.2959	0.0143	0.3409	0.0042	0.1145	0.3524
Romo	Vertebral- vBMD (mg / cm ³)	0.6706	< 0.0001	0.4814	< 0.0001	0.5635	< 0.0001
	Pedicle - vBMD (mg / cm ³)	0.5342	< 0.0001	0.6253	< 0.0001	0.2814	0.0201
-	Spine- aBMD (g / cm ²)	0.1191	0.7124	-0.0424	0.8956	0.1189	0.7129
ELD	Vertebral- vBMD (mg / cm ³)	0.4308	0.1621	0.1414	0.6613	0.8531	0.0004
	Pedicle - vBMD (mg / cm ³)	0.4308	0.1621	0.9188	< 0.0001	0.6573	0.0202
	2	Vertebral strength		Pullout strength		Cage subsidence strength	
	3 months	r	р	r	р	r	Р
II	Vertebral- vBMD (mg / cm ³)	0.7106	< 0.0001	0.5470	< 0.0001	0.6294	< 0.0001
7	Pedicle - vBMD (mg / cm ³)	0.5805	< 0.0001	0.6946	< 0.0001	0.3896	0.0004
omo	Vertebral- vBMD (mg / cm ³)	0.7474	< 0.0001	0.5324	< 0.0001	0.6177	< 0.0001
Rc	Pedicle - vBMD (mg / cm ³)	0.5854	< 0.0001	0.6658	< 0.0001	0.3421	0.0043
ΓD	Vertebral- vBMD (mg / cm ³)	0.8392	0.0006	0.7874	0.0024	0.8392	0.0006
Ē	Pedicle - vBMD (mg / cm ³)	0.4755	0.1182	0.8647	0.0003	0.7413	0.0006

469 Table2. The regional BMD is well correlated with the biomechanical parameters.

470



472 The biomechanical parameters exhibited significant correlations with each BMD measurement and

473 showed a stronger correlation with the regional vBMD measured by QCT.

474 aBMD: areal bone mineral density, vBMD: volumetric bone mineral density

475 Figure 1. Overview of *in silico* drug assessment for instrumentation surgery



- 477 The proposed framework for drug assessment in instrumentation surgery.
- 478 **a**, CT scans, pre- and post-treatment, with a calibration phantom for quality longitudinal measurements.
- 479 **b**, Creation of the 3D (dimensional) vertebral models from the CT data. **c**, Regional 3D v-BMD
- 480 measurements provide accurate BMD assessment. d, Biomechanical evaluations of surgical-related
- 481 parameters using the finite element method.



482 Figure2. Romosozumab rapidly increases vBMD in the vertebral body and pedicle.

483	a , Image illustrating the 3D model of the vertebrae and dimensions in both the axial and sagittal views.
484	Color map representing the distribution of bone mineral density (mg/mm ³). b , Representative axial
485	images of BMD distribution at baseline and 3 months. c, Enlarged images of the axial view of the pedicle
486	and vertebral body showing the improvement in BMD with romosozumab treatment in both the pedicle
487	and vertebral body. d, Representative sagittal images of BMD at baseline and 3 months. e, Enlarged
488	images of the sagittal view of the cage's corresponding area and inner cortical region of the pedicle,
489	showing the BMD increase with romosozumab. f. g, Percentage changes of vertebral-vBMD and pedicle-
490	vBMD between groups following 3 months of treatment. Data are expressed as medians (interquartile
491	ranges). Differences between groups were analyzed using Mann–Whitney U test. *: $P < 0.05$, **: $P < 0.05$, *
492	0.01, ***: P < 0.001, ****: P < 0.0001. vBMD: volumetric bone mineral density



493 Figure3. Romosozumab resulted in improvement in all the biomechanical analyses

a, Representative images illustrating the compression strength analysis under a 3500 N load, following
treatment. The upper images depict the distribution of yield risk (%), while the lower images show the
distribution of elements associated with high-risk crushing [yield elements (yellow) and compressive
failure elements (red)] both at baseline and 3 months. High yield risk and an increase in crushed elements
suggest the potential risk of vertebral fracture. b, Representative images showing the pullout strength
analysis results when a 200 N force was applied to extract the screw. The upper images depict the
distribution of yield risk (%), while the lower images show the distribution of elements associated with

- 502 high-risk crushing. High yield risk and an increase in crushed elements suggest a potential risk of screw
- 503 loosening. c, Representative images illustrating the cage subsidence strength when a load of 400 N was
- applied. The upper images depict the distribution of yield risk (%), while the lower images show the
- 505 distribution of elements associated with high-risk crushing. High yield risk and an increase in crushed
- 506 elements suggest a potential risk of cage subsidence. d-e, Percentage changes in biomechanical
- 507 parameters between groups following 3 months of treatment. Data are expressed as medians
- 508 (interquartile ranges). Differences between groups were analyzed using Mann–Whitney U test. *: P <
- 509 0.05, **: P < 0.01, ***: P < 0.001.

510	Supplemental Information (Table S1, Figure S1-6, Movie S1-4)
511	
512	The potential effect of romosozumab on perioperative management for
513	instrumentation surgery
514	
515	Koji Ishikawa ^{1,2,3*} , Soji Tani ¹ , Koki Tsuchiya ¹ , Tomoko Towatari ¹ , Yusuke Oshita ⁴ , Ryo Yamamura ¹ ,
516	Toshiyuki Shirahata ² , Katsunori Inagaki ¹ , Tomoaki Toyone ¹ , Yoshifumi Kudo ¹
517	
518	¹ Department of Orthopaedic Surgery, School of Medicine, Showa University, Tokyo, Japan
519	² Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan
520	³ Department of Orthopaedic Surgery, Duke University, North Carolina, USA
521	⁴ Department of Orthopaedic Surgery, Showa University Northern Yokohama Hospital, Kanagawa, Japan
522	⁵ Department of Orthopaedic Surgery, Showa University Koto Toyosu Hospital
523	
524	*Corresponding author: Koji Ishikawa (K.I)
525	Department of Orthopaedic Surgery, School of Medicine, Showa University, Tokyo, Japan
526	Address: Building No.6, room517, 1-5-8 Hatanodai, Shinagawa, Tokyo 142-8666, Japan
527	Tel: +81 3 3784 8543 Fax: +81 3 3784 9005
528	Email: koji.ishikawa@med.showa-u.ac.jp
529	

530 Supplemental table1 Materials properties of each element for finite element models

	Young's Modulus (E) (MPa)	Poisson's Ratio	Yield Stress (σ) (MPa)	Critical Stress (MPa)	Element type	Size/Thickness
Bone	Keyak (equation 1)	0.4	Keyak (equation 2)	$\mathbf{St} = \mathbf{0.8Sm}$	Tetrahedral solid	Less than 2 mm / -
Cortical shell	*	0.4	Keyak (equation 2)	$\mathbf{St} = \mathbf{0.8Sm}$	Triangular plate	$2\ mm/0.4\ mm$
Cement cap (PMMA)	2500	0.35	20.6	75.0	Tetrahedral solid	2 mm/-
Pedicle screw (Titanium alloy)	108853.8	0.28	899.3	824.7	Tetrahedral solid	Less than 1 mm / -
Cage (PEEK)	3.6	0.3	90.0	90.0	Tetrahedral solid	Less than 1 mm / -

Equation 1

$$\mathbf{E} = \begin{cases} 0.001(\rho = 0) \\ 33900\rho^{2.20}(0 < \rho \le 0.27) \\ 5307\rho + 469(0.28 < \rho < 0.6) \\ 10200\rho^{2.01}(0.6 \le \rho) \end{cases}$$

Equation 2
$$\sigma = \begin{cases} 1.0 * 10^{20}(\rho \le 0.2) \\ 137\rho^{1.88}(0.2 < \rho < 0.317) \\ 114\rho^{1.72}(0.317 < \rho) \end{cases}$$

- *Young's Modulus of the cortical shell was determined by the Hounsfield unit, selecting the value of its
- adjacent bone unless it was lower than 1000, in which case a value of 1000 was used.
- 534 PMMA; poly(methyl-methacrylate), PEEK; polyetheretherketone

535 Supplemental figure 1. The regions of interest for both pedicle-vBMD and vertebral-vBMD.



- 537 The red and blue areas illustrate the ROI of the pedicle-vBMD and vertebral-vBMD, respectively. The
- 538 ROI for the pedicle-vBMD and vertebral-vBMD were manually defined so as to cover the corresponding
- area, consistent with previous reports (6,18).
- 540 ROI: region of interest, vBMD: volumetric bone mineral density.

541 Supplemental figure2. Study diagram

542



543

Between March 2019 and March 2021, 400 patients had osteoporosis treatment. 226 patients who were
scheduled for romosozumab (Romo) or eldecalcitol (ELD) treatment were assessed for inclusion, with 81
participating in the present study. Patients were divided into two groups based on their treatment (Romo:
69 patients, ELD: 12 patients), and 66 patients (95.7%) from the Romo group and 10 patients (83.3%)
from the ELD group completed 6 month follow-up.

549 Supplemental figure3. Safety profile of romosozumab treatment for 6 months



550

551 The incidence rate of adverse events during 6 months of romosozumab treatment. Blue dots represent patients without any adverse events, whereas the orange dots represent patients who experienced adverse 552 events. Twenty-one patients (30.4%) experienced adverse events following romosozumab treatment. 553 554 Injection-site reactions were reported by 16 patients (23.2%). Hypocalcemia and hypercalcemia were observed in one patient each (1.5%), respectively. Gastroenteritis was reported by one patient (1.5%). 555 556 Two (2.9%) patients having severe adverse events included one stroke and one death leading to 557 discontinuation of treatment. These severe adverse events were not thought to be associated with the 558 treatment.

559 Supplemental figure4. Overview of injection site reactions during romosozumab treatment



560

a, Distribution of injection site reactions. b, Proportion of patients experienced multiple injection site
reactions.

563 Twenty-two injection-site reactions were reported in 16 patients (23.2%) in the romosozumab group.

These reactions were most common at the initial injection (50.0%). Among the patients who had

565 injection-site reactions, five patients (7.3%) experienced these reactions multiple times (2 times: 4

566 patients, 3 times: 1 patient) during the course of the study.



567 Supplemental figure5. Changes in bone turnover markers during the 6-month treatment

568

572

a, Percentage change from baseline in total P1NP. b, Absolute change from baseline in total P1NP, c, 569

Percentage change from baseline in TRACP-5b. d, Absolute change from baseline in TRACP-5b. 570

571 In the Romo group, the P1NP level peaked at 3 months, and the percentage change from baseline of total P1NP was higher compared to the ELD group at both 3 and 6 months. The TRACP-5b levels decreased

significantly in both groups, with no significant difference observed between the groups. Data are 573

574 expressed as medians (interquartile ranges). The difference in the continuous measures across the groups

was compared using a one-way analysis by the Dunn test. Differences between groups were analyzed 575

using the Mann–Whitney U test. *: P < 0.05, **: P < 0.01, ***: P < 0.001, ***: P < 0.001, ns: not 576

significant. 577

578 total P1NP: total N-terminal propeptide of type 1 procollagen, TRACP-5b: tartrate-resistant acid 579 phosphatase 5b.

580 Supplemental figure6. Spine-aBMD assessed by DXA increased significantly following



581 romosozumab treatment at 6 months.

582

583 Percentage changes of spine-aBMD between groups following 6 months of treatment.

a, Percentage change in all patients. **b**, Percentage change in patients with treatment naïve.

585 aBMD: areal bone mineral density

586 Supplemental Movie1. The modeling methods of a 3D vertebra

A 3D model of the spine was created based on the CT data, then the L4 vertebra was constructed with
2mm tetrahedral solid elements and 2-mm triangular plates using MECHANICAL FINDER software
(version 12.0 extended edition; Research Center of Computational Mechanics, Tokyo, Japan). Each
element was assigned individual mechanical properties, and the bone mineral density was integrated to

591 account for bone heterogeneity.

592 Supplemental Movie2. Finite element analysis for compression strength

593 A compressive displacement was applied to the PMMA (poly methyl-methacrylate) cement cap at the

594 cranial end of the vertebrae, with displacement increments of 0.01 mm / step. The time segment from

595 0:07-0:17 depicts the distribution of high-risk elements associated with crushing [yield elements (yellow)

and compressive failure elements (red)], while 0:18-0:41 illustrates the distribution of yield risk. High

597 yield risk and an increase in compressive failure elements suggest a potential risk for compression

598 fracture.

599 Supplemental Movie3. Finite element analysis for pullout strength

A screw was implanted according to the conventional pedicle screw trajectory. The vertebra was fully fixed in all directions, and an incremental tensile loading rate of 20 Newton (N) / step was applied to the screw head. From 0:06-0:17 the images show the distribution of high-risk elements associated with crushing [yield elements (yellow) and compressive failure elements (red)], while 0:18-0:30 illustrates the distribution of yield risk. High yield risk and an increase in compressive failure elements suggest a potential risk for compression fracture.

606 Supplemental Movie4. Finite element analysis for cage subsidence strength

607 A PEEK (polyetheretherketone) cage was positioned 5-mm behind the anterior edge of the upper endplate

608 vertebrae to assess the risk of cage subsidence. A compressive displacement was applied to the PEEK

609 cage at the cranial end of the vertebrae, using ramped displacement increments of 0.01 mm / step. The

- time segment of the 0:05-0:15 images shows the distribution of high-risk elements associated with
- 611 crushing [yield elements (yellow) and compressive failure elements (red)], while 0:20-0:30 illustrates the
- 612 distribution of yield risk. High yield risk and an increase in compressive failure elements suggest a
- 613 potential risk of cage subsidence.